fingolimod (Gilenya) vs Ponesimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
fingolimod (Gilenya)
Marketed by Novartis and partners
NCT00289978 · Phase 3 · completed
This was a large randomized, triple-blind, placebo-controlled Phase 3 trial in 1,272 people with multiple sclerosis, using the annualized relapse rate as its primary measure. Both fingolimod doses roughly halved that rate against placebo: 0.16 relapses per year (95% CI 0.13 to 0.19) on 1.25 mg and 0.18 (95% CI 0.15 to 0.22) on 0.5 mg, against 0.40 (95% CI 0.34 to 0.47) on placebo. The registry posts these rates without a statistical test, but the intervals do not overlap, so the direction of the effect is not in doubt.
Next expected readout: January 2030 · NCT07220252 (registry estimate)
Reported efficacy
Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47) (met)
Result source: NCT00289978
Ponesimod
Marketed by Vanda Pharmaceuticals and partners
NCT02425644 · Phase 3 · completed
This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.
Reported efficacy
Annualized Confirmed Relapse Rate (From randomization to end of study (Week 108)): Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. (met)
Result source: NCT02425644
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fingolimod (Gilenya) | Ponesimod |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.4−0.2 vs placeboNCT002899785 other results
| 0.2 vs 0.3vs TeriflunomideNCT02425644 |
| Free of 3-month confirmed disability progression (%) | 82.3% vs 75.9%+6.4 vs placeboNCT002899783 other results
| —Not reported |
| New or enlarging T2 lesions | 2.5 vs 9.8−7.3 vs placeboNCT002899781 other result
| —Not reported |
Annualised relapse rate
- fingolimod (Gilenya)
- 0.2 vs 0.4−0.2 vs placeboNCT00289978
5 other results
- 0.2 vs 0.4 NCT00355134
- 0.2 vs 0.4 NCT00289978
- 0.2 vs 0.4 NCT00355134
- 0.2 vs 0.4 NCT00355134
- 0.2 vs 0.4 NCT00355134
- Ponesimod
- 0.2 vs 0.3vs TeriflunomideNCT02425644
Free of 3-month confirmed disability progression (%)
- fingolimod (Gilenya)
- 82.3% vs 75.9%+6.4 vs placeboNCT00289978
3 other results
- 74.7% vs 71% NCT00355134
- 83.4% vs 75.9% NCT00289978
- 78.3% vs 71% NCT00355134
- Ponesimod
- —Not reported
New or enlarging T2 lesions
- fingolimod (Gilenya)
- 2.5 vs 9.8−7.3 vs placeboNCT00289978
1 other result
- 2.5 vs 9.8 NCT00289978
- Ponesimod
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. fingolimod (Gilenya): 6 of 6 rows · Ponesimod: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fingolimod (Gilenya) Rows use multiple source trials | Ponesimod Rows use multiple source trials |
|---|---|---|
| Annualized Relapse event rate · per year No placebo or comparator arm | 0.169 per year @ 676wk0.5 mg/Daya,b,c,d NCT01201356 · Phase 3 · registry result, not featured evidence | 0.142 per year20 mge,a,b,c,d NCT01093326 · Phase 2 · registry result, not featured evidence show 2 more doses0.15 per year40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 0.205 per year10 mg NCT01093326 · Phase 2 · registry result, not featured evidence |
| Time to First Relapse time to event · months No placebo or comparator arm | NA monthse,f,b,c,d NCT01498887 · Phase 4 · registry result, not featured evidence show 1 more doseNA months NCT01498887 · Phase 4 · registry result, not featured evidence | 151.55 months*20 mge,f,b,c,d NCT01093326 · Phase 2 · registry result, not featured evidence · converted to months from 656.7 weeks as posted show 2 more doses99.62 months*40 mg NCT01093326 · Phase 2 · registry result, not featured evidence · converted to months from 431.7 weeks as posted 62.84 months*10 mg NCT01093326 · Phase 2 · registry result, not featured evidence · converted to months from 272.3 weeks as posted |
| Dropout rate | 13.2%0.5 mgg NCT00289978 · Phase 3 · monotherapy show 44 more results22.6%1.25 mg NCT00289978 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy 7.7%0.5 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy 13.4%1.25 mg NCT00340834 · Phase 3 · monotherapy 13.2%0.5 mg NCT00662649 · Phase 3 · monotherapy —0.5 mg NCT00662649 · Phase 3 —0.5 mg NCT00662649 · Phase 3 22.6%1.25 mg NCT00662649 · Phase 3 · monotherapy —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy 9.1%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 13.8%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 33.3% NCT02232061 · Phase 4 · registry result, not featured evidence 43%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 15.7%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 31% NCT01705236 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02373098 · Phase 4 · registry result, not featured evidence 18.2%FTY720 NCT02373098 · Phase 4 · registry result, not featured evidence 0.5% NCT01585298 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02720107 · Phase 4 · registry result, not featured evidence 8%Naive or de Novo Participants NCT01498887 · Phase 4 · registry result, not featured evidence 7.5%Previously Treated With First-line NCT01498887 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01333501 · Phase 4 · registry result, not featured evidence 14.2% NCT01623596 · Phase 4 · registry result, not featured evidence 12.1% NCT02048072 · Phase 4 · registry result, not featured evidence 16.7% NCT01578330 · Phase 4 · registry result, not featured evidence 5.2%0.5 mg NCT01534182 · Phase 4 · registry result, not featured evidence 9.6%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence —0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 15.6%0.5 mg/Day NCT01201356 · Phase 3 · registry result, not featured evidence 6.8%0.5 mg NCT01497262 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 24%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 32.2%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 2.1% NCT01199861 · Phase 3 · registry result, not featured evidence 19.1%0.5 mg NCT00670449 · Phase 2 · registry result, not featured evidence 21.7%1.25 mg NCT00670449 · Phase 2 · registry result, not featured evidence | 13.6%20 mgg NCT02425644 · Phase 3 show 4 more results19.8%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 33.9%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 35%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 38.3%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%0.5 mgg NCT00289978 · Phase 3 · monotherapy show 44 more results5.1%1.25 mg NCT00289978 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy 2.1%0.5 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy 6.1%1.25 mg NCT00340834 · Phase 3 · monotherapy 3.1%0.5 mg NCT00662649 · Phase 3 · monotherapy —0.5 mg NCT00662649 · Phase 3 —0.5 mg NCT00662649 · Phase 3 5.1%1.25 mg NCT00662649 · Phase 3 · monotherapy —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy 0%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 2.3%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence — NCT02232061 · Phase 4 · registry result, not featured evidence 15.2%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 5.5%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 5.7% NCT01705236 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02373098 · Phase 4 · registry result, not featured evidence 4.5%FTY720 NCT02373098 · Phase 4 · registry result, not featured evidence 0.3% NCT01585298 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02720107 · Phase 4 · registry result, not featured evidence 2%Naive or de Novo Participants NCT01498887 · Phase 4 · registry result, not featured evidence 0.7%Previously Treated With First-line NCT01498887 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01333501 · Phase 4 · registry result, not featured evidence 4.6% NCT01623596 · Phase 4 · registry result, not featured evidence 9.1% NCT02048072 · Phase 4 · registry result, not featured evidence 4.8% NCT01578330 · Phase 4 · registry result, not featured evidence 3%0.5 mg NCT01534182 · Phase 4 · registry result, not featured evidence 5.1%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence —0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 4.1%0.5 mg/Day NCT01201356 · Phase 3 · registry result, not featured evidence 1.2%0.5 mg NCT01497262 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 6.1%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 7.6%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 1.1% NCT01199861 · Phase 3 · registry result, not featured evidence 12.8%0.5 mg NCT00670449 · Phase 2 · registry result, not featured evidence 4.3%1.25 mg NCT00670449 · Phase 2 · registry result, not featured evidence | 2.3%20 mgg NCT02425644 · Phase 3 show 4 more results1.6%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 0.8%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 3.4%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 1.7%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 10.1%0.5 mgg NCT00289978 · Phase 3 · monotherapy show 44 more results11.9%1.25 mg NCT00289978 · Phase 3 · monotherapy 7%0.5 mg NCT00340834 · Phase 3 · monotherapy 14.5%0.5 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy 10.7%1.25 mg NCT00340834 · Phase 3 · monotherapy 15.3%1.25 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00662649 · Phase 3 · monotherapy 9.4%0.5 mg NCT00662649 · Phase 3 7.1%0.5 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy 10.7%1.25 mg NCT00662649 · Phase 3 11.7%1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy —0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence —0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 33.3% NCT02232061 · Phase 4 · registry result, not featured evidence 5.5%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 5.5%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 12.6% NCT01705236 · Phase 4 · registry result, not featured evidence 4.5%0.5 mg NCT02373098 · Phase 4 · registry result, not featured evidence —FTY720 NCT02373098 · Phase 4 · registry result, not featured evidence 2.3% NCT01585298 · Phase 4 · registry result, not featured evidence 0%0.5 mg NCT02720107 · Phase 4 · registry result, not featured evidence 5.5%Naive or de Novo Participants NCT01498887 · Phase 4 · registry result, not featured evidence 2.7%Previously Treated With First-line NCT01498887 · Phase 4 · registry result, not featured evidence 8.7%0.5 mg NCT01333501 · Phase 4 · registry result, not featured evidence 6.7% NCT01623596 · Phase 4 · registry result, not featured evidence 6.1% NCT02048072 · Phase 4 · registry result, not featured evidence 9.5% NCT01578330 · Phase 4 · registry result, not featured evidence 0.9%0.5 mg NCT01534182 · Phase 4 · registry result, not featured evidence 4%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 3.6%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 12.6%0.5 mg/Day NCT01201356 · Phase 3 · registry result, not featured evidence 7.4%0.5 mg NCT01497262 · Phase 3 · registry result, not featured evidence 14.8%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 6.5%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 14.3%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 8.8%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 1.1% NCT01199861 · Phase 3 · registry result, not featured evidence 17%0.5 mg NCT00670449 · Phase 2 · registry result, not featured evidence 10.9%1.25 mg NCT00670449 · Phase 2 · registry result, not featured evidence | 8.7%20 mgg NCT02425644 · Phase 3 show 4 more results12.8%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 24.1%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 16.6%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 23%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 0.5 mgg nasopharyngitis 27.1% (placebo 27.5%) headache 25.2% (placebo 23%) upper respiratory tract infection 17.2% (placebo 17.2%) NCT00289978 · Phase 3 · monotherapy show 34 more results1.25 mg headache 26.3% (placebo 23%) nasopharyngitis 26.1% (placebo 27.5%) upper respiratory tract infection 14.5% (placebo 17.2%) NCT00289978 · Phase 3 · monotherapy 0.5 mg nasopharyngitis 25.4% upper respiratory tract infection 17.5% lymphopenia 15.7% NCT00662649 · Phase 3 0.5 mg nasopharyngitis 28.4% headache 16.8% upper respiratory tract infection 15.5% NCT00662649 · Phase 3 1.25 mg nasopharyngitis 28.4% lymphopenia 18% upper respiratory tract infection 13.5% NCT00662649 · Phase 3 1.25 mg nasopharyngitis 26.9% upper respiratory tract infection 15.9% headache 12.4% NCT00662649 · Phase 3 anxiety 16.7% bursitis 16.7% facet joint syndrome 16.7% NCT02232061 · Phase 4 · registry result, not featured evidence 0.5 mg headache 8% lymphopenia 5.5% pain in extremity 5.5% NCT03257358 · Phase 4 · registry result, not featured evidence 0.5 mg fall 5.5% urinary tract infection 3.2% arthralgia 2.8% NCT03257358 · Phase 4 · registry result, not featured evidence nasopharyngitis 47.1% multiple sclerosis relapse 24.1% hypertension 13.8% NCT01705236 · Phase 4 · registry result, not featured evidence 0.5 mg influenza 3% gamma-glutamyltransferase increased 1.5% headache 1.5% NCT02373098 · Phase 4 · registry result, not featured evidence headache 4.5% fatigue 3.2% nasopharyngitis 2% NCT01585298 · Phase 4 · registry result, not featured evidence 0.5 mg blood immunoglobulin m decreased 0.8% NCT02720107 · Phase 4 · registry result, not featured evidence headache 8.5% nasopharyngitis 8% upper respiratory tract infection 7.5% NCT01498887 · Phase 4 · registry result, not featured evidence headache 11.6% urinary tract infection 10.2% upper respiratory tract infection 8.2% NCT01498887 · Phase 4 · registry result, not featured evidence 0.5 mg headache 10.6% alanine aminotransferase increased 8.7% depression 6.7% NCT01333501 · Phase 4 · registry result, not featured evidence fatigue 11.3% nasopharyngitis 9.5% headache 9.2% NCT01623596 · Phase 4 · registry result, not featured evidence exacerbation of migraines 3% NCT02048072 · Phase 4 · registry result, not featured evidence urinary infection 21.4% upper respiratory infection 19% lymphopenia 16.7% NCT01578330 · Phase 4 · registry result, not featured evidence 0.5 mg lymphopenia 11.7% gamma-glutamyltransferase increased 5.7% alanine aminotransferase increased 4.8% NCT01534182 · Phase 4 · registry result, not featured evidence 0.5 mg/day headache 12.4% fatigue 11.5% upper respiratory tract infection 6.5% NCT01216072 · Phase 4 · registry result, not featured evidence 0.5 mg/day headache 9.8% nausea 5.7% fatigue 5.2% NCT01216072 · Phase 4 · registry result, not featured evidence 0.5 mg/Day nasopharyngitis 17.3% headache 8.5% upper respiratory tract infection 8.5% NCT01201356 · Phase 3 · registry result, not featured evidence 0.5 mg headache 13.6% lymphopenia 10.5% fatigue 6.2% NCT01497262 · Phase 3 · registry result, not featured evidence 0.5 mg upper respiratory tract infection 24.3% (placebo 24.2%) nasopharyngitis 23.5% (placebo 23.9%) headache 23.2% (placebo 21.4%) NCT00355134 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16% (placebo 23.9%) upper respiratory tract infection 12.3% (placebo 24.2%) headache 9% (placebo 21.4%) NCT00355134 · Phase 3 · registry result, not featured evidence 1.25 mg upper respiratory tract infection 24.9% (placebo 24.2%) nasopharyngitis 23.8% (placebo 23.9%) headache 21.9% (placebo 21.4%) NCT00355134 · Phase 3 · registry result, not featured evidence 1.25 mg nasopharyngitis 16.2% (placebo 23.9%) upper respiratory tract infection 15.9% (placebo 24.2%) sinusitis 10.1% (placebo 12.7%) NCT00355134 · Phase 3 · registry result, not featured evidence headache 18.9% (placebo 9.3%) nasopharyngitis 15.8% (placebo 18.6%) upper respiratory tract infection 11.6% (placebo 14%) NCT01199861 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 61.7% headache 17% liver function test abnormal 12.8% NCT00670449 · Phase 2 · registry result, not featured evidence 1.25 mg nasopharyngitis 60.9% liver function test abnormal 17.4% lymphopenia 17.4% NCT00670449 · Phase 2 · registry result, not featured evidence | 20 mgg alanine aminotransferase increased 19.5% nasopharyngitis 19.3% headache 11.3% NCT02425644 · Phase 3 show 4 more results20 mg covid-19 26.2% nasopharyngitis 18.7% alanine aminotransferase increased 16.6% NCT03232073 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 31.7% headache 21.4% upper respiratory tract infection 19.3% NCT01093326 · Phase 2 · registry result, not featured evidence 40 mg nasopharyngitis 29.8% headache 27.2% upper respiratory tract infection 25.8% NCT01093326 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 33.1% headache 27.3% upper respiratory tract infection 19.4% NCT01093326 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 2 versus Phase 4.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fingolimod (Gilenya)
show 3 more results
show 1 more result
show 17 more results
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 9 more results
show 1 more result
show 23 more results
show 9 more results
+ 141 further endpoints in the CSV export.
Ponesimod
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fingolimod (Gilenya)'s landscape · Ponesimod's landscape